Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00642967 |
This single arm study will assess the efficacy and safety of monthly administration of subcutaneous Mircera when administered for the maintenance of hemoglobin levels in patients with chronic renal anemia, not on dialysis. Patients currently receiving treatment with subcutaneous epoetin or darbepoetin alfa will receive monthly subcutaneous injections of Mircera, with the starting dose (120 or 200 micrograms) calculated from the last weekly dose of ESA previously administered. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Condition | Intervention | Phase |
---|---|---|
Anemia |
Drug: methoxy polyethylene glycol-epoetin beta |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Single Arm, Open Label, French Multi-Centre Study to Assess the Maintenance of Hemoglobin Levels With Once Monthly Subcutaneous Administration of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease Not on Dialysis |
Estimated Enrollment: | 250 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | May 2010 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: methoxy polyethylene glycol-epoetin beta
s.c. every 4 weeks (starting dose based on previous ESA therapy)
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Please reference Study ID Number: ML21146 | 973-235-5000 | |
Contact: or | 800-526-6367 (FOR US ONLY) |
Study Director: | Clinical Trials | Hoffmann-La Roche, +1 973 235 5000 |
Responsible Party: | Hoffmann-La Roche ( Clinical Trials, Study Director ) |
Study ID Numbers: | ML21146, 2007-005757-28 |
Study First Received: | March 19, 2008 |
Last Updated: | April 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00642967 History of Changes |
Health Authority: | France: Agence francaise de securite sanitaire des produits de sante (AFSSAPS) |
Epoetin Alfa Renal Insufficiency Urologic Diseases Hematologic Diseases Renal Insufficiency, Chronic |
Anemia Kidney Failure, Chronic Kidney Diseases Kidney Failure |
Renal Insufficiency Urologic Diseases Hematologic Diseases Renal Insufficiency, Chronic |
Kidney Failure, Chronic Anemia Kidney Diseases Kidney Failure |